Medable is partnering with Masimo to bring medical-grade wearable devices to clinical research. Masimo’s pulse oximeter technology is now enabling more patients to participate in clinical trials without the burdens of ongoing trips to the trial site for routine testing.
Medable has integrated Masimo’s MightySat Rx pulse oximeter into its evidence-generation platform for eight big-pharma-sponsored clinical trials spanning 25 countries including over 3,000 patients across two oncology indications: lung and breast cancer. The device integration eliminates significant travel burdens from often very sick patients while empowering them to participate in potentially lifesaving clinical trials. With this partnership, Medable also enables both subjective data capture – via humans through Medable’s eCOA+ solution – and objective data capture via Masimo’s connected sensors for multifaceted, deeper data analysis in trials.
Medable selected Masimo for its reputation and Signal Extraction Technology that delivers accurate readings in challenging conditions, such as patient motion or low perfusion.
Currently, 20% of trials leveraging Medable’s evidence generation platform include a wearable device, and 35% of those are in oncology.
